Chimeric antigen receptor-T cell (CAR-T) therapy is an exciting treatment modality for blood cancers that…
Chimeric antigen receptor (CAR) cell therapy offers hope where other cancer therapies have failed. However,…
CAR-T therapy has been hailed as a cure for cancer, but what really is this…
The microbiome could pave new cancer immunotherapy inroads for European biotechs, bolstered by preclinical findings…
The UK biotech Adaptimmune Therapeutics has inked a deal worth up to €806M with Japanese…
London-based Autolus has shown its next-generation CAR T-cell therapy does not induce some of the…
The Belgian company Celyad has released the first interim clinical efficacy data for an off-the-shelf…
The UK biotech Autolus’ shares have slumped as construction delays from a new manufacturing site…
Celyad is one of many companies in the immuno-oncology field seeking to take the lead…
In biotechnology, plasmids are commonly used as vectors for the replication and cloning of recombinant…
Cell Medica’s next-generation CAR-T cell therapy has resulted in 'extensive tumor regression' in a…
The UK biotech Cell Medica has received a €7.6M ($8.7M) grant from the Cancer Prevention…
